Telitacicept might be a new treatment option for MCD patients with poor response to long-term glucocorticoids. Prednisone 30 mg/day and tacrolimus 1 mg/day led to complete remission after 8-month treatment, but the disease recurred after reducing the prednisone dose. Minimal change disease (MCD) is a common pathological type of idiopathic nephrotic syndrome.[1] The first-line therapy is prednisone,[2] but steroid-sensitive forms frequently relapse.